Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-06

SCTX vs XFOR: stock comparison and AI forecast

Scribe Therapeutics, Inc. (SCTX) and X4 Pharmaceuticals, Inc (XFOR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Biological Products, (No Diagnostic Substances)

SCTX Scribe Therapeutics, Inc.

Price
$16.78 -45.7% · 6M
Market Cap
$318M
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Biological Products, (No Diagnostic Substances)

XFOR X4 Pharmaceuticals, Inc

Price
$3.07 -28.4% · 6M
Market Cap
$304M
P/E Ratio
1.4x
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

6M · 2026-09-02 → 2026-11-05

Six-month price performance

Closing prices rebased to 100 at the start of the window.

607590105
SCTX -45.7% XFOR -28.4%
SCTX · XFOR

Key facts

  • SCTX and XFOR have similar market capitalizations ($318M and $304M).
  • Over the last six months XFOR returned -28.4% and SCTX -45.7%.
  • Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricSCTXXFOR
Market Cap$318M$304M
P/E Ratio–1.44x
P/B Ratio–2.19x
EPS–$2.13
Book Value/Share–$1.40
Revenue/Share–$0.10

Profitability & Margins

MetricSCTXXFOR
ROIC–-37.1%
Gross Margin–88.0%
Operating Margin–-812.8%
EBT Margin–-810.9%
Tax Rate–-0.0%

Financial Health

MetricSCTXXFOR
Current Ratio0.57x13.22x
Quick Ratio–13.21x
D/E Ratio–0.67x
Financial Leverage–1.67x
Interest Coverage-10.7x-2.9x
Working Capital-$34M$183M

Cash Flow

MetricSCTXXFOR
Operating Cash Flow–-$76M

Operational Efficiency

MetricSCTXXFOR
Asset Turnover–0.04x
Receivables Turnover–6.7x
Inventory Turnover–12.1x
Fixed Assets Turnover–173.5x
Days Sales Outstanding–54 days
Days Inventory–30 days
Payables Period–577 days
Cash Conversion Cycle–-492 days

Income Statement

MetricSCTXXFOR
Total Revenue–$10M
Operating Income–-$80M
R&D Expense–$62M
Cost of Goods Sold–$3M

Dividend & Shareholder Information

MetricSCTXXFOR
Shares Outstanding19M99M
FAQ

SCTX vs XFOR: stock comparison and AI forecast

Which is bigger, SCTX or XFOR?

SCTX and XFOR have similar market capitalizations ($318M and $304M).

Which stock performed better over the last six months, SCTX or XFOR?

Over the last six months XFOR returned -28.4% and SCTX -45.7%.

Which one does Intratio's AI model rank higher, SCTX or XFOR?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.